Company Description
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States.
The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds.
In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth.
It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013.
Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Edward V. Pershing CPA |
Contact Details
Address: 800 S. Gay Street, Suite 1610 Knoxville, Tennessee 37929 United States | |
| Phone | (866) 594-5999 |
| Website | provectusbio.com |
Stock Details
| Ticker Symbol | PVCT |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000315545 |
| CUSIP Number | 74373P108 |
| ISIN Number | US74373P1084 |
| Employer ID | 90-0031917 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dominic Rodrigues C.F.A., CFA | Chief Operations Consultant and Vice Chairman of the Board |
| Dr. Eric A. Wachter | Co-Founder and Chief Technology Officer |
| Heather Raines CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 3, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 25, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K | Current Report |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | ARS | Filing |
| May 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 6, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2024 | 10-K/A | [Amend] Annual report |